Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 3/20 | 0.71 |
| ▸ | TLR1 | Q15399 | 3/20 | 0.71 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22179377 | 1.00 | TLR2 (0.71) | TLR2TLR1TAAR1POLBKMT2A | |
| SCHEMBL22179374 | 1.00 | TLR2 (0.71) | TLR2TLR1TAAR1POLBKMT2A | |
| SCHEMBL22179361 | 1.00 | TLR2 (0.71) | TLR2TLR1TAAR1POLBKMT2A | |
| SCHEMBL22622464 | 0.90 | TLR2 (0.65) | TLR2TLR1TAAR1POLBKMT2A | |
| SCHEMBL22179370 | 0.90 | TLR2 (0.65) | TLR2TLR1TAAR1POLBKMT2A | |
| SCHEMBL22179368 | 0.90 | TLR2 (0.65) | TLR2TLR1TAAR1POLBKMT2A | |
| SCHEMBL22622467 | 0.90 | TLR2 (0.59) | TLR2TLR1TAAR1POLBKMT2A | |
| SCHEMBL22160600 | 0.85 | TLR2 (0.76) | TLR2TLR1TAAR1POLBKMT2A | |
| SCHEMBL22160576 | 0.85 | TLR2 (0.76) | TLR2TLR1TAAR1POLBKMT2A | |
| SCHEMBL22160628 | 0.85 | TLR2 (0.76) | TLR2TLR1TAAR1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040959-B2 | Diprovocims: a new and potent class of TLR agonists | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200207742-A1 | DIPROVOCIMS: A NEW AND POTENT CLASS OF TLR AGONISTS | THE SCRIPPS RESEARCH INSTITUTE | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207742-A1 | DIPROVOCIMS: A NEW AND POTENT CLASS OF TLR AGONISTS | TLR1, TLR4, TLR2 | TLR2 3/4885TLR1 1/4885TAAR1 584/4885 |
| US-11040959-B2 | Diprovocims: a new and potent class of TLR agonists | TLR1, TLR4, TLR2 | TLR2 3/4885TLR1 1/4885TAAR1 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.